COVID-19 has sadly become a familiar name across the globe. It has evolved into an incomparable menace, leaving serious illness and death in its wake. Yet, there is hope. Emerging research reveals that a medication created in 1963, Naltrexone, shows promise as a method of treatment for patients with mild to moderate symptoms of COVID-19.
In the 1980s, the Food and Drug Administration (FDA) approved high doses of this drug as a treatment to help people fight the battle of opioid dependence and alcoholism.
Bernard Bihari, MD later discovered that very low doses of naltrexone boosted endorphin levels and helped patients’ immune systems function correctly. Subsequently named LDN (Low Dose Naltrexone), professionals recognized this medication’s potential to help people suffering from multiple sclerosis, HIV/AIDS, and other inflammatory diseases.
This disease can strike a terrible blow to many sufferers because it tricks the immune system into overreacting. For the body to coordinate its amazing ability to fight microscopic invaders, its immune system needs communication among its cells. Proteins called cytokines enable this communication. Yet, COVID-19 triggers our defensive system to release large numbers of cytokines that are disproportionate to the threat or are no longer needed.
Thanks to this cytokine storm, the immune system attacks the body’s own tissues. Thus, it may generate organ failure and more damage than the virus itself.
Studies show that LDN has the ability to block these hyperinflammatory cytokines and prevent a cytokine storm. Additionally, LDN has shown its value by stopping SARS-CoV-2 from binding to the body’s cells. Even more promising research shows that LDN combines with other drugs for COVID treatment, a process known as adjuvant therapy.
Clinical trials are being conducted that are looking at the potential impact of other medications combined with LDN for the treatment of post-COVID 19 syndrome. Colchicine and Nicotinamide Adenine Dinucleotide (NAD+) are two agents under investigation.
Clinical trials have proven colchicine useful in treating inflammatory disorders involving blood vessels, cardiac damage, and other problems. Since LDN boasts an immune-boosting ability and limits excessive responses, clinical trials are hopeful that a combination of these drugs may reduce the progression of symptoms in patients dealing with COVID-19.
Pandemic sufferers experiencing post-COVID-19 syndrome may find hope in studies exploring the combination of LDN and NAD+. Nicotinamide Adenine Dinucleotide, a helper molecule, produces naturally within the body in every cell. It is known for its support role in healthy aging and it is hoped that its combination with LDN may reduce the fatigue experienced by sufferers of this syndrome.
In response to this unique pandemic, innovative research is racing along at an unprecedented pace today. The potential for LDN’s role in treating this disease brings hope for multiple treatment options. If you’re looking to learn more about LDN and its other benefits, Kefi Health can help you get started.
Kefi Health has medical-grade wellness options for modern women, backed by science and nature. From advanced testing to weight loss treatments.
Media Contact
Company Name: Kefi Health
Contact Person: Dr. Kimberly Derezil, MD
Email: Send Email
Phone: (484) 229-6798
Country: United States
Website: http://www.kefihealth.com/